De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors.
Journal
American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
revised:
02
01
2024
received:
30
11
2023
accepted:
08
01
2024
pubmed:
6
2
2024
medline:
6
2
2024
entrez:
6
2
2024
Statut:
ppublish
Résumé
Overall survival of patients classified according to the European LeukemiaNet 2020 classification. Chronic phase (CP), accelerated phase (AP), blast crisis (BC), low risk (LR), intermediate risk (IR), high risk (HR).
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
763-766Subventions
Organisme : Ministerstvo Zdravotnictví Ceské Republiky
ID : 00023736
Organisme : Ministerstvo Zdravotnictví Ceské Republiky
ID : 00669806
Organisme : Ministerstvo Školství, Mládeže a Tělovýchovy
ID : LX22NPO5102
Organisme : Ministerstvo Školství, Mládeže a Tělovýchovy
ID : MUNI/A/1558/2023
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Foley TH, Bennett JM, Carbone PP. Combination chemotherapy in accelerated phase of chronic granulocytic leukemia. Arch Intern Med. 1969;123:166-170.
Kantarjian HM, Dixon D, Keating MJ, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer. 1988;61:1441-1446.
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391-2405.
Arber DA, Orazi A, Hasserjian R, et al. International consensus classification of myeloid neoplasms and acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200-1228.
Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966-984.
Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36:1703-1719.
Kantarjian HM, Tefferi A. Classification of accelerated phase chronic myeloid leukemia in the era of the BCR::ABL1 tyrosine kinase inhibitors: a work in progress. Am J Hematol. 2023;98:1350-1353.
Pfirrmann M, Baccarani M, Saussele S, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2015;30:48-56.